These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25886680)

  • 1. Psychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gap.
    Levy E; Traicu A; Iyer S; Malla A; Joober R
    Can J Psychiatry; 2015 Mar; 60(3 Suppl 2):S48-52. PubMed ID: 25886680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit hyperactivity disorder and comorbid psychosis: a review and two clinical presentations.
    Pine DS; Klein RG; Lindy DC; Marshall RD
    J Clin Psychiatry; 1993 Apr; 54(4):140-5. PubMed ID: 8098031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ADD psychosis: treatment with antipsychotics and methylphenidate?].
    Blom JD; Kooij JJ
    Tijdschr Psychiatr; 2012; 54(1):89-93. PubMed ID: 22237615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy.
    Merrill RM; Thygerson SM; Palmer CA
    Pharmacopsychiatry; 2016 Mar; 49(2):45-50. PubMed ID: 26829453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First episode psychosis and comorbid ADHD, autism and intellectual disability.
    Strålin P; Hetta J
    Eur Psychiatry; 2019 Jan; 55():18-22. PubMed ID: 30384107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan.
    Shyu YC; Yuan SS; Lee SY; Yang CJ; Yang KC; Lee TL; Wang LJ
    Schizophr Res; 2015 Oct; 168(1-2):161-7. PubMed ID: 26363968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tourette Syndrome and comorbid ADHD: current pharmacological treatment options.
    Rizzo R; Gulisano M; Calì PV; Curatolo P
    Eur J Paediatr Neurol; 2013 Sep; 17(5):421-8. PubMed ID: 23473832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antipsychotic agents and stimulants: a judicious combination?].
    de Jong MH; Eussen ML; van Gool AR
    Tijdschr Psychiatr; 2010; 52(1):57-61. PubMed ID: 20054798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting.
    Corbeil O; Brodeur S; Courteau J; Béchard L; Huot-Lavoie M; Angelopoulos E; Di Stefano S; Marrone E; Vanasse A; Fleury MJ; Stip E; Lesage A; Joober R; Demers MF; Roy MA
    Br J Psychiatry; 2024 Mar; 224(3):98-105. PubMed ID: 38044665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series.
    Tossell JW; Greenstein DK; Davidson AL; Job SB; Gochman P; Lenane M; Nugent Iii TF; Gogtay N; Sporn AL; Rapoport JL
    J Child Adolesc Psychopharmacol; 2004; 14(3):448-54. PubMed ID: 15650502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Response to 'ADD psychosis: treatment with antipsychotics and methylphenidate?'].
    Vergouwen T; Gorissen-Van Eenige M
    Tijdschr Psychiatr; 2012; 54(3):308; author reply 309. PubMed ID: 22422425
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychostimulants in the treatment of adults with psychosis and attention deficit disorder.
    Opler LA; Frank DM; Ramirez PM
    Ann N Y Acad Sci; 2001 Jun; 931():297-301. PubMed ID: 11462748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.
    Linton D; Barr AM; Honer WG; Procyshyn RM
    Curr Psychiatry Rep; 2013 May; 15(5):355. PubMed ID: 23539465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of psychiatric comorbidity with attention-deficit/hyperactivity disorder.
    Pliszka SR
    Child Adolesc Psychiatr Clin N Am; 2000 Jul; 9(3):525-40, vii. PubMed ID: 10944655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of psychostimulants in pervasive developmental disorders.
    Abanilla PK; Hannahs GA; Wechsler R; Silva RR
    Psychiatr Q; 2005; 76(3):271-81. PubMed ID: 16080422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epilepsy and comorbid neurodevelopmental disorders].
    Nordin V; Olsson IB; Tomson T
    Lakartidningen; 2018 May; 115():. PubMed ID: 29786810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
    Kollins SH
    J Atten Disord; 2008 Sep; 12(2):115-25. PubMed ID: 18192623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The psychopharmacology of the comorbid disorders associated with attention deficit hyperactivity disorder].
    de la Osa-Langreo A; Mulas F; Téllez de Meneses M; Gandía R; Mattos L
    Rev Neurol; 2007 Mar; 44 Suppl 2():S31-5. PubMed ID: 17347942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed Amphetamine Salts Without a Mood Stabilizer for Treating Comorbid Attention-Deficit Hyperactivity Disorder and Bipolar Disorder: Two Case Reports.
    Armstrong C; Kapolowicz MR
    Mil Med; 2023 May; 188(5-6):e1316-e1319. PubMed ID: 34318326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
    Kollins SH
    Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.